Synofarm booster doses were found to be vulnerable to Omicron: study

The Covid booster dose developed by Sinopharm in China has been shown to produce a weaker immune response against new, highly contagious Omicron variants that are known to evade vaccine efficacy.

The hypermutant Omicron mutant strains of concern have spread to approximately 90 countries to date, raising serious concerns about reduced vaccine efficacy and increased risk of reinfection.

In one study, researchers at Shanghai Jiao Tong University and a Shanghai-based laboratory specializing in respiratory infections compared the activity of China National Pharmaceutical’s booster vaccine with older people. coronavirus Stocks from Wuhan.

Studies that have not yet been peer-reviewed have shown that the neutralizing antibody activity of China National Pharmaceutical BBIBP-CorV booster against Omicron showed a 20.1-fold reduction compared to its activity against Wuhan strains.

The study included 292 healthcare workers who received a third allogeneic booster vaccination 8-9 months after the completion of two priming inactivated vaccines.

The team investigated whether the newly identified Omicron mutant could avoid serum antibody neutralization induced by booster immunization vaccination.

The results showed that a third booster dose with BBIBP-CorV resulted in a significant rebound in neutralizing the immune response to SARS-CoV-2. The neutralization titer on the 28th day after the third booster immunization was 6.1 times higher than that on the 28th day after the second dose.

However, “Omicron mutants caused significantly lower neutralization sensitivities compared to wild-type strains of booster-induced sera and were reduced by approximately 20.1-fold,” said Xin-xin Zhang, School of Medicine, Ruijin Hospital.

“Our study showed that a third booster dose of BBIBP-CorV resulted in a significant rebound in neutralizing the immune response to SARS-CoV-2.

Another study, which has not yet been peer-reviewed, showed that a double-dose vaccine against Covid in Synofarm also produced little or no antibody against Omicron.

The study, led by researchers at the University of Washington and the Swiss pharmaceutical company Humabs Biomed SA, showed that only 3 out of 13 people who took shots of both doses of Synofarm showed neutralizing antibodies to Omicron. I did.

Meanwhile, the vaccine developed by US pharmaceutical companies Pfizer, Moderna, Johnson, and Johnson against Covid-19 proved to be less effective against the new super-mutant Omicron variant, which contains up to 36 mutations in the spike protein. It has been.

–IANS

rvt / ksk /

(Only the headings and images in this report may have been recreated by Business Standard staff. The rest of the content is automatically generated from the syndicated feed.)

Dear reader,

Business Standards has always worked hard to provide you with the latest information and commentary on developments that are of interest to you and have a wide range of political and economic impacts on the country and the world. Your encouragement and constant feedback on how to improve our offerings only strengthened our determination and commitment to these ideals. Even during these difficult times resulting from Covid-19, we keep you up-to-date with credible news, authoritative views, and sharp commentary on issues of relevant topics. I will continue to promise to keep it.
However, there is a request.

We need more support to continue to provide higher quality content as we fight the economic impact of the pandemic. Our subscription model has seen encouraging reactions from many who subscribe to our online content. Increasing your subscription to online content only helps you reach your goal of delivering better, more relevant content. We believe in free, fair and reliable journalism. Your support through more subscriptions will help us practice the journalism we are committed to.

Supporting high quality journalism, Subscribe to business standards..

Digital editor